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Summary. The localization of fructose-1,6-bis- 
phosphatase (Fru-1,6-Pase EC 3.1.3.11) in human 
alveolar epithelium was determined immunohisto- 
chemically using a polyclonal antibody raised against 
the enzyme purified from human liver. The immuno- 
histochemical analysis revealed that the Fru-1,6-Pase 
was localized in pneumocytes 11 and was  absent 
in pneumocytes 1. Hypothetically Fru-1,6-Pase 
participating in glucose-6-phosphate synthesis from 
noncarbohydrate precursors increases NADPH leve1 
which is used for surfactant synthesis and for glutathione 
redox cycle. 
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lntroduction 
Fructose-1,6-bisphosphatase (Fru-1,ó-Pase E C  
3.1.3.11) catalyzes hydrolysis of fructose-1,6- 
bisphosphate to fructose-6-phosphate and inorganic 
phosphate in the presence of such divalent cations like 
magnesium, manganese, zinc or cobalt. Monovalent 
cations are needed for  the enzyme to achieve i ts  
maximum activity (Benkovic and DeMaine, 1982; 
Tejwani, 1983). The enzyme is inhibited competitively 
by fructose-2,6-bisphosphate and allosterically by AMP 
(Pilkis et al., 1981; Van Schaftingen et al., 1980). Brain, 
muscle and liver Fru-1,6-Pase isozymes have been found 
in mammalian tissue (Horecker et al., 1975; Tejwani, 
1983; Liu and Frornrn, 1988). The physiological role of 
brain isozyme is unknown. Muscle isozyme participates 
in glycogen synthesis from lactate (McLane and 
Holloszy, 1979; Hermansen and Vaage, 1979) and is 
Offprint requests to: Dr. Andrzej Dzugaj, Departrnent of Animal 
Physiology, lnstitute of Zoology, Wroclaw University, Cybulskiego 30, 
Wroclaw, Poland. Fax: (48 71) 322-28-17. e-rnail: dzugajan@ 
biol.uni.wroc.pl 
involved in glycolysis regulation via futile cycle 
(Newsholme and Start, 1976). Liver isozyme also found 
in kidney, intestine and monocytes are recognized as a 
regulatory enzyme of gluconeogenesis (Mizunuma and 
Tashima, 1978; Tejwani, 1983). It has been suggested 
that besides liver and kidney lung is  also a 
gluconeogenic organ. Latres et al. (1992) have observed 
glucose production by rat lung in a double cannulation 
system. Recently we have reported on purification of 
Fru-1,6-Pase from human lung (Skalecki et al., 1999). 
Based upon Western blot analysis, determined kinetic 
properties, as well as cDNA coding region, the lung Fru- 
1,6-Pase has been found to be identical with the liver 
isozyme. Since lung tissue is rather a heterogeneous 
population of cells (Crystal et al., 1997) w e  have 
attempted to locate Fru-l ,6-Pase in lung cells.  
Previously, immunocytochemical investigation has been 
performed in order to map the cellular distribution of 
Fru-1,6-Pase in rat kidney and liver (Saez et al., 1996). 
Immunofluorescence studies of rat brain sections have 
demonstrated that Fru-l,6-Pase is an astrocyte-specific 
enzyme (Schmoll et al., 1995). Our paper is the first 
report on the localization of Fru-1,6-Pase in lung cells. 
The evidence presented here indicates that human lung 
Fru-l,6-Pase is  localized in pneumocytes 11. The  
physiological meaning of this finding is discussed. 
Materials and methods 
Human lung tissue samples were removed surgically 
from 7 patients of the Lower Silesian Pulmonary Center. 
They were men, aged 49 to 60 years (mean 58 years) 
with histologically proven diagnosis of squamous cell 
lung cancer. The tumor was located in hillus and for this 
reason pneumonectomy was performed. Lung tissues 
were taken from the dista1 part of bronchus without 
pleura. The samples were taken in agreement with the 
rules of The Scientific Research Ethical Cornmittee. 
Large Volume Peroxidase Kit, Antibody diluent with 
background reducing components and DAB chromogen 
FBP-ase is present  in pneumocytes 11 
were purchased from DAKO (USA), Canada balsam and 
Para& wax were from Fluka (Fuchs, Switzerland) and 
xylene, CH30H, NaCl, H203 were obtained from POCh 
(Gliwice, Poland). Al1 other reagents were from Sigma 
(St. Louis, USA). All of the reagents were of the highest 
purity commercially available. 
Antibody production 
Antiserum against the human liver Fru-l,6-Pase was 
raised in rabbit by intracutaneous injection of the 
purified enzyme (4 mg; isolated from human liver 
according to Dzugaj and Kochman (1980)) and Freund's 
complete adjuvant. Immuneserum was partially purified 
using acetone powder from human liver. Reactivity of 
anti-Fru-1,6-Pase serum was estimated using double 
diffusion method (Clausen, 1988). Immunodiffusion 
resulted in a strong reaction between the antiserum and 
the pure enzyme. 
lmmunocytochemistry 
Human lung tissue samples were fixed in Bouin 
solution for 24 hours at room temperature. After the 
fixation they were dehydrated and embedded in paraffin. 
5 p sections were cut from the blocks of tissues and 
mounted on slides. Before immunostaining, sections 
were deparaffinized and treated with 1% H202 for 30 
minutes to inhibit endogeneous peroxidase. Then they 
were incubated with normal goat serum (1:20), with 
rabbit polyclonal antibodies against human liver Fru-1,6- 
Pase (1:2500) overnight at 4 OC and at room temperature 
for 1 hour, with biotin-labelled goat antirabbit IgG for 15 
minutes and with streptavidin-peroxidase complex for 15 
minutes (SAB - modified ABC method where 
streptavidin was substituted for avidin). Each incubation 
was followed by three washings with PBS. Finally the 
peroxidase reaction was  developed using 3,3'- 
diaminobenzidine (DAB) (Hsu e t  al., 1981) and 
examined by light microscopy. 
Controls 
In control reactions either the primary antibody was 
omitted or nonimmune rabbit serum was used as a first 
layer. 
Results 
Anti-Fru-1,6-Pase antibodies reacted with cuboidal 
cells on the surface of lung alveoli (Fig. 1). No reaction 
of anti-Fru-1,6-Pase antibodies with lining alveoli flat 
cells nor with intercellular barrier was observed. This 
indicates the presence of Fru-1,6-Pase in pneumocytes 
11. No macrophages were observed on the surface of 
alveoli which might interact with anti-Frul,6-Pase 
antibodies impeding pneumocytes 11 distinction. 
When the anti-Fru-1,6-Pase serum was omitted or 
nonimmune serum was used peroxidase reaction was not 
observed. 
Discussion 
The alveolar epithelium is composed of squamous 
pneumocytes 1 and cuboidal pneumocytes 11. 
Pneumocytes 1 constitute ca 8%, pneumocytes 11 - 15% 
of the lung cells. Pneumocytes 1 are highly evolved to 
function a s  a thin gas permeable membrane. 
Flg. 1. Human lung sections stained with 
anti-Fru-l,6-Pase antibodies and SAB 
method. Brown colour indicates positive 
staining (DAB reaction). Positive 
irnmunoreaciion is noted in pneurnocytes 
II but not in pneurnocytes l. x 400 
FBP-ase is present in pneumocytes 11 
Pneumocytes 11 are recognized as the cells that 
synthesize and secret pulmonary surface-active material 
- the surfactant. Numbers of papers have been published 
on surfactant synthesis; many fewer publications deal 
with lung carbohydrate metabolism and still fewer with 
lung gluconeogenesis. 
Recently we found liver Fru-l,6-Pase isozyme in 
human lung tissue. Liver Fru-l,6-Pase is a key enzyme 
of gluconeogenesis. Its activity is regulated by fructose- 
2,6-bisphosphate whose concentration is under hormonal 
control. Fru-l,6-Pase participates in synthesis of 
glucose-6-phosphate which is hydrolyzed by glucose-6- 
phosphatase and released to the blood stream. Activity of 
glucose-6-phosphatase in lung is much lower than in 
liver (Skalecki et al., 1999). In lung the excess of 
glucose-6-phosphate might be used for glycogen 
synthesis or be oxidized by glucose-6-phosphate 
dehydrogenase. The oxidation of glucose-6-phosphate 
results in NADPH synthesis, which is a substrate for 
surfactant synthesis. NADPH also plays an important 
role in protection of cellular proteins and lipids against 
oxidizing effect of oxygen radicals. 
We hypothesized that Fru-l,6-Pase participating in 
synthesis of glucose-6-phosphate was involved in a 
protection of lung cells against toxic effect of oxygen as 
well as in a surfactant production. Although the main 
source of glucose-6-phosphate is glucose from blood, an 
additional supply of glucose-6-phosphate seemed to be 
advantageous. Pneumocytes 1, the very large flat cells 
that line more than 90% of the alveolar surface are 
exposed on increased partial pressure of oxygen. On the 
other hand, surfactant synthesis is localized in 
pneumocytes 11. Therefore, we expected that Fru-1,6- 
Pase should be localized in both types of pneumocytes. 
Contrary to our expectations Fru-l,6-Pase was detected 
only in pneumocytes 11. Its presence in surfactant 
synthesizing cells supports our hypothesis that this 
enzyme participates in synthesis of glucose-6-phosphate 
from noncarbohydrate precursors facilitates surfactant 
synthesis. The absence of Fru-1,6-Pase in pneumocytes 1 
does not apparently support our hypothesis on its 
participation in protection of lung cells against toxic 
effect of oxygen. It has been reported that pneumocytes 1 
do not contain catalase (Crystal et al., 1997) and this 
may indirectly indicate that these cells are less sensitive 
to oxygen radicals. Pneumocytes 11, which supposedly 
are very sensitive to oxygen radicals, contain al1 sets 
of antioxidant enzymes and nonenzymatic oxygen 
radical scavengers (Crystal et al., 1997). In other 
words Fru-1,6-Pase is present in pneumocytes 11, since 
it increases total production of NADPH, which is 
used in surfactant synthesis and for glutathione redox 
cycle. 
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